December 2015

FDA updates blood donor referral policy

Tuesday, December 22, 2015

The FDA has issued final guidance outlining updated blood donor deferral recommendations to help ensure continued safety of the blood supply by reducing the risk of human immunodeficiency virus (HIV) transmission by blood and blood products. [Read More]

The informed consent process

Monday, December 21, 2015

The Pulse on Study Conduct by Elizabeth Weeks-Rowe

To provide an informed consent process that’s transparent and equitable is the most sacrosanct assurance of safety we can provide research patients.

[Read More]

Three Questions: Piet van der Graaf, Certara

Monday, December 21, 2015

CW Weekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trial space. Staff writer Ron Rosenberg interviewed Piet van der Graaf, Pharm.D., Ph.D., vice president of quantitative systems pharmacology at Certara and former director of XenologiQ, a QSP consultancy.

[Read More]

Tetragenetics launches mAbs partnership program

Friday, December 18, 2015

Tetragenetics, an emerging biotechnology company engaged in the expression of ion channel drug targets, has announced a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states—such as pain and autoimmune disorders.

[Read More]